Corcept Therapeutics Incorporated (CORT) reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of 28 cents per share in the year-ago quarter.Revenues in the third quarter increased 48% year over year to $182.5 million. The figure also beat the Zacks Consensus Estimate of $172 million. The top line solely comprises product sales of Cushing’s syndrome drug, Korlym.Corcept's shares were down 10.5% in afte ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Conference Call Participants David Amsellem - Piper Sandler Matt Kaplan - Ladenburg Swayampakula Ramakanth - H. C. Wainwright Joon Lee - Truist Operator Good day and thank you for standing by. Welcome to the Corcept Therapeutics Conference Call. At this time, all p ...

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 51.85%. A quarter ago, it was expected that this drug developer would post earnings of $0.23 per share when it actually produced earnings of $0.32, delivering a surprise of 39.13%. Over the last four quarters ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 ________________ ...

EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS, POSITIVE RESULTS FROM PHASE 3 GRADIENT TRIAL IN PATIENTS WITH CUSHING'S SYNDROME AND PROVIDES CORPORATE UPDATE • Revenue of $182.5 million, a 48 percent increase over the same period in 2023 • Increase in 2024 revenue guidance to $675 – $700 million, from $640 – $670 million • Net income per common share of $0.41 (diluted), compared to $0.28 in third quarter 2023 • Cash and investments of $547.6 million as of September 30, 2024 • R ...

Corcept Therapeutics (CORT) shares soared 5.5% in the last trading session to close at $49.75. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 15.3% gain over the past four weeks.The company’s sole marketed drug, Korlym, approved for treating Cushing's syndrome, is witnessing strong demand and driving growth. Also, a new drug application for the lead candidate, relacorilant, to treat Cushing’s syndrome is expected to be filed lat ...

Shares of Corcept Therapeutics (CORT) have gained 11.8% over the past four weeks to close the last trading session at $47.27, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $67.60 indicates a potential upside of 43%. The average comprises five short-term price targets ranging from a low of $45 to a high of $78, with a standard deviation of $13.32. While the lowest estimate indi ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate re ...

Our initiation report " "Corcept Therapeutics - Three Dynamic Catalysts To Reaccelerate Growth" on September 15, 2024 became so long we had to save some content for this new report which focuses on the important near term news flow for Brown University Ab.ScB Civil Engineering/Urban Studies, Stanford University MBA, Morgan Guaranty Trust, Fiduciary Trust International ,Tanaka Capital Mgmt., Author "Digital Deflation" McGraw-Hill 2004. Appeared on CNBC and Bloomberg TV 40+ times. Manages the TANAKA Growth Fu ...

Corcept Therapeutics' (CORT) sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing strong demand in the past couple of quarters. The company is also making good progress with its promising set of pipeline candidates. The successful development and commercialization of its pipeline candidates will be an added boost to the company. Let's dig deeper. Reasons to Invest in CORT Stock Good Rank and Rising Estimates: Cor ...